kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human DNAM-1 / CD226 Protein, His Tag, 2x500µg  

Recombinant Human DNAM-1 / CD226 Protein, His Tag, 2x500µg

Recombinant Human DNAM-1 /CD226 Protein, Glu 19 - Asn 247, produced in human 293 cells (HEK293), His Tag

recombinant, human, protein DNAM1,CD226

More details


Availability: within 7 days

1 500,00 €

DNAX accessory molecule 1 (DNAM-1), a single-pass type I membrane protein, is also known as CD226 antigen and platelet and T cell activation antigen 1 (PTA1), which contains 2 Ig-like C2-type (immunoglobulin-like) domains. DNAM-1 is a ~65 kDa glycoprotein expressed on the surface of natural killer cells, platelets, monocytes and a subset of T cells. DNAM-1 mediates cellular adhesion to other cells bearing its ligands, CD112 and CD155, and cross-linking DNAM-1 with antibodies causes cellular activation. Furthermore, DNAM-1 can interact with PVR and PVRL2.

Recombinant Human DNAM-1 /CD226 Protein (rh DNAM-1 / CD226) Glu 19 - Asn 247 (Accession # NP_006557) was produced in human 293 cells (HEK293).

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 27.9 kDa. The protein migrates as 36-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg of the rh DNAM-1 / CD226 by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Immobilized Human DNAM-1, His Tag (Cat. No. DN1-H52H6) at 2μg/mL (100 μL/well) can bind Human CD155, Fc Tag (Cat. No. CD5-H5251) with a linear range of 3.3-51.2 ng/mL (QC tested).

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).


(1) Shibuya A., et al.,1995, Immunity 4:573-581.
(2) Tahara-Hanaoka S., et al .,2003, Int. Immunol. 16:533-538.
(3) Pende D., et al.,2004, Mol. Immunol. 42:463-469.